Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Shares Outstanding (Weighted Average): 2023-2025

Historic Shares Outstanding (Weighted Average) for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $28.0 million.

  • Contineum Therapeutics' Shares Outstanding (Weighted Average) rose 9.01% to $28.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 9.01%. This contributed to the annual value of $25.8 million for FY2024, which is 41.20% up from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Shares Outstanding (Weighted Average) is $28.0 million, which was up 8.39% from $25.9 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Shares Outstanding (Weighted Average) peaked at $28.0 million during Q3 2025, and registered a low of $18.3 million during Q4 2023.
  • For the 3-year period, Contineum Therapeutics' Shares Outstanding (Weighted Average) averaged around $24.2 million, with its median value being $25.8 million (2024).
  • Data for Contineum Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 41.72% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Contineum Therapeutics' Shares Outstanding (Weighted Average) stood at $18.3 million in 2023, then skyrocketed by 41.20% to $25.8 million in 2024, then grew by 9.01% to $28.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $28.0 million in Q3 2025, compared to $25.9 million in Q2 2025 and $25.9 million in Q1 2025.